The Menlo Park, CA-based company’s 50,000-patient trial will launch in 2019 and could be one of the most significant events of the year for the liquid biopsy market.
Daxor’s new technology designed to measure blood volume has the potential to reduce patient readmission rates and improve outcomes for patients suffering from acute heart failure.
Doctors need more tools to quickly determine whether an antibiotic is truly needed, an expert tells MD+DI.
A startup spawned from Oxford University is trying to commercialize components of a quantum computing technology that could ultimately improve the downstream end of existing diagnostic devices.
The Madison, WI-based company said its test can identify metabolic subtypes associated with the Autism Spectrum and can be used to screen children as young as 18 months.
Diagnostics manufacturer OpGen is partnering with ILUM and the NY State Department of Health to detect, track, and manage antimicrobial-resistant infections at healthcare institutions statewide.
A panel of IVD experts will discuss the latest in vitro diagnostic trends at the BIOMEDevice San Jose conference in December.
It's been a full year since Abbott closed its $5.3 billion acquisition of Alere, a deal that almost didn't happen.
Rapid testing results could encourage more-appropriate use of antibiotics, and this flu season could put that theory to work.
Aromyx Corp. announces its groundbreaking biosensor technology based on the human sense of smell and taste. The company says the new technology has the potential to be used as a diagnostic tool to detect early stage cancer and disease.
Quadrant Biosciences scored a $2 million NIH grant to supports its epigenetic diagnostic test for autism spectrum disorder.
Seven key trends and events helped make Liquid Biopsy attractive to investors, shareholders, patients, and physicians.